Compare ADMA Biologics Inc (ADMA) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Dropbox Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Dropbox Inc trades at $28.76 (market cap $6.73B). The key difference: Dropbox Inc is far larger — about 3.2× ADMA Biologics Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DBX | |
|---|---|---|
Market Cap | $2.13B | $6.73B |
Sector | Health | Technology |
52-Week High | $20.38 | $32.17 |
52-Week Low | $7.60 | $22.06 |
Enterprise Value | $2.20B | $9.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
DBX trades at $28.85, up 1.02% today, with a bullish technical signal from moving averages and a consensus price target of $30.00. The company maintains strong profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent developments include a new $900 million stock repurchase program and CEO transition news from Reuters on 2026-05-26.
Outlook remains positive with steady revenue near $2.5 billion and robust cash flow, though risks include high debt levels and competitive pressures. The stock offers moderate upside to the price target with support from buybacks, but investors should monitor execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
